Hallo! Tracked shipping to Netherlands with Delivery Duty Paid for just €7 

Ship to
Netherlands
0
  • argentina
  • chile
  • colombia
  • españa
  • méxico
  • perú
  • estados unidos
  • internacional

Select your country

Americas

Europe

Rest of the world

portada Combination Therapy in Dyslipidemia
Type
Physical Book
Publisher
Language
English
Pages
205
Format
Paperback
Dimensions
23.4x15.6x1.2 cm
Weight
0.31 kg.
ISBN13
9783319367217
Edition No.
1

Combination Therapy in Dyslipidemia

Banach, Maciej (Author) · Adis · Paperback

Combination Therapy in Dyslipidemia - Banach, Maciej

Cheaper New Book Imported to Netherlands
Delivery: 18 Dec - 22 Dec Shipping: 16 to 17 business days.
€ 100,90
Faster New Book Imported to Netherlands
Delivery: 04 Dec - 08 Dec Shipping: 6 to 7 business days.
€ 123,28
Import costs and 9% BTW included in the price ✅
€ 100,90

Synopsis "Combination Therapy in Dyslipidemia"

Comprising contributions from leading lipidologists from around the world, this book presents the latest and most comprehensive knowledge on the different options for combination therapy of dyslipidemia and includes discussion of future therapies that are currently in late stages of clinical evaluation. Dyslipidemia is a leading cause of cardiovascular morbidity and mortality and most patients with this condition fail to achieve adequate control of their serum lipid levels with monotherapy. However, recent US and European guideline recommendations, based on randomized, controlled trials, fail to discuss combination therapy options for patients with dyslipidemia.Statins remain the mainstay of drug therapy for hyperlipidemia and chapters in this book specifically examine the role of add-on therapy with different agents modulating the different lipid fractions in the blood, e.g. bile acid sequestrants, fibric acid derivatives (fibrates), omega-3 fatty acids (fish oils), inhibitors of Niemann-Pick C1 like 1 (NPC1L1) protein, cholesteryl ester transfer protein (CETP), apolipoprotein B-100 and microsomal triglyceride transfer protein (MTP) and the emerging proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. There is additional discussion of the role of non-drug therapy options such as nutraceuticals, functional foods and lipoprotein apheresis. The book also discusses the combination of antihypertensive drugs with lipid-lowering drugs in the management of cardiovascular risk in patents with dyslipidemia.

Customers reviews

Frequently Asked Questions about the Book

All books in our catalog are Original.
The book is written in English.
The binding of this edition is Paperback.

Questions and Answers about the Book

Do you have a question about the book? Login to be able to add your own question.

Opinions about Bookdelivery

More customer reviews